Oncology
Excerpt from the Press Release: CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced additional details pertaining to Cullinan Pearl’s ongoing Phase 1/2a trial of CLN-081 in Non-Small Cell Lung Cancer (NSCLC) patients whose tumors harbor epidermal…
Read More
Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–As part of the 2021 ASCO Annual Meeting, precision oncology company Lucence is sharing real-world data supporting clinical applications of its amplicon-based liquid biopsy assay. The data will be presented in on-demand virtual poster sessions, available beginning June 4 at 9 AM EDT. Lucence is also announcing…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. & NEW ORLEANS–(BUSINESS WIRE)–Harvard University has granted an exclusive license to biotechnology company Obatala Sciences to commercialize innovations that enable the study of human fat tissue in vitro. Harvard Office of Technology Development and Obatala, which manufactures stem cell and hydrogel products to enable next-generation therapeutics discovery, announced the agreement today. Obatala…
Read More
Excerpt from the Article: PHILADELPHIA—An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy, according to a new study from researchers at the University of Pennsylvania and Penn’s Perelman School of Medicine. The findings suggest that the Penn-developed tool…
Read More
Excerpt from the Press Release: BOSTON and LAUSANNE, Switzerland, June 1, 2021 /PRNewswire/ — SOPHiA GENETICS, the creator of a global data-sharing network that advances data-driven medicine, today released SOPHiA DDM™ for Blood Cancers, novel blood cancer testing solutions across the entire workflow from setup, genomic testing, and in-house advanced analytics. The solutions target the most relevant DNA variants and RNA fusion genes…
Read More
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result. Researchers at Washington University School of Medicine in St. Louis used the Naveris, Inc. test to analyze saliva for sequences of the human papilloma virus (HPV)…
Read More
Excerpt from the Press Release: BOSTON and MONTRÉAL, May 27, 2021 /PRNewswire/ – enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 in patients with BCG-unresponsive non-muscle…
Read More
Excerpt from the Announcement: The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) that would attract partnerships and/or investment for further preclinical and clinical…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) — Senti Bio, a leading gene circuit company, today announced presentations on its gene circuit engineered allogeneic CAR-NK cell therapy pipeline at the International Society for Cell and Gene Therapy (ISCT) Virtual Annual Meeting. The presentations provide details of Senti Bio’s…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced results from a randomized confirmatory Phase 2 study of ficlatuzumab as a single agent or in combination with cetuximab (ERBITUX®), an EGFR-targeted antibody, in patients who relapsed or were refractory to prior immunotherapy, chemotherapy, and…
Read More